Novo-Nordisk A/S closed at $40.65 on Nov 12, down 1.07%, 36.5% below its 52-week closing high. Volume of 15.7M shares was 1.39× its 20-day average (above normal).
Split-adjusted performance: +6.6% over one month, -11.2% over six months, -17.3% over one year.
Short interest was 38.3M shares at the Oct 30 settlement, up 2.3% from the prior report (4.0 days to cover).
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment.
What is NVO's market cap?
$179.20B, based on the Nov 12 close of $40.65.
Does Novo-Nordisk A/S pay a dividend?
Yes. The latest regular dividend was $0.5792 per share (ex-date Aug 17), an annualised yield of 2.85%.
About Novo-Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
